Clinical Trial Update: A Study to Evaluate the Immunogenicity, Safety, and Tolerability of VARIVAX™ Manufactured With a New Process (V210-062) [Phase 3]

View source ↗

Summary

A Phase 3 trial evaluating a new manufacturing process for VARIVAX to immunize against varicella has been withdrawn.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Varicella

Drugs mentioned

• Varivax (varicella vaccine (live attenuated))

Snippet

Sponsor: Merck Sharp & Dohme LLC | Conditions: Varicella | Phase 3 | Status: WITHDRAWN